Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 1;347(2):159-66.
doi: 10.1016/j.canlet.2014.03.013. Epub 2014 Mar 19.

Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches

Qiong Wu  1 , Zhiping Yang  1 , Yongzhan Nie  1 , Yongquan Shi  2 , Daiming Fan  3
Affiliations
Review

Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches

Qiong Wu et al. Cancer Lett. .

Abstract

Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer chemotherapies. The mechanisms of MDR and the approaches to test MDR have been discovered, yet not fully understood. This review covers the in vivo and in vitro approaches for the detection of MDR in the laboratory and the mechanisms of MDR in cancers. This study also envisages the future developments toward the clinical and therapeutic applications of MDR in cancer treatment. Future therapeutics for cancer treatment will likely combine the existing therapies with drugs originated from MDR mechanisms such as anti-cancer stem cell drugs, anti-miRNA drugs or anti-epigenetic drugs. The challenges for the clinical detection of MDR will be to find new biomarkers and to determine new evaluation systems before the drug resistance emerges.

Keywords: Biomarker; Cancer; Chemotherapy; Lab approach; Mechanism; Multi-drug resistance (MDR).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources